docid_page,row,col,value,baseline_level_1,arms,subgroup_name,outcomes,subgroup_name;p-interaction,measures;arms,arms;measures,measures,subgroup_level,arms;p-interaction;other,arms;measures;p-interaction,arms;other
29143919_1,3,2,59.5 ± 9.4,Age (years),iGlarLixi,All completers (n 5 327),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,3,3,60.7 ± 9.5,Age (years),iGlarLixi,HbA1c <= 8% (n 5 97),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,3,4,59.1 ± 9.8,Age (years),iGlarLixi,8% < HbA1c <= 9% (n 5 161),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,3,5,58.6 ± 8.2,Age (years),iGlarLixi,HbA1c > 9% (n 5 69),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,3,6,60.5 ± 8.4,Age (years),iGlar,All completers (n 5 333),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,3,7,61.4 ± 7.8,Age (years),iGlar,HbA1c <= 8% (n 5 94),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,3,8,59.9 ± 8.1,Age (years),iGlar,8% < HbA1c <= 9% (n 5 158),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,3,9,60.7 ± 9.6,Age (years),iGlar,HbA1c >9% (n 5 81),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,4,2,55.4,Female (%),iGlarLixi,All completers (n 5 327),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,4,3,52.6,Female (%),iGlarLixi,HbA1c <= 8% (n 5 97),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,4,4,57.1,Female (%),iGlarLixi,8% < HbA1c <= 9% (n 5 161),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,4,5,55.1,Female (%),iGlarLixi,HbA1c > 9% (n 5 69),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,4,6,52.6,Female (%),iGlar,All completers (n 5 333),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,4,7,51.1,Female (%),iGlar,HbA1c <= 8% (n 5 94),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,4,8,51.9,Female (%),iGlar,8% < HbA1c <= 9% (n 5 158),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,4,9,55.6,Female (%),iGlar,HbA1c >9% (n 5 81),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,5,2,12.1 ± 6.7,Duration of T2D (years),iGlarLixi,All completers (n 5 327),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,5,3,11.9 ± 6.8,Duration of T2D (years),iGlarLixi,HbA1c <= 8% (n 5 97),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,5,4,11.6 ± 6.1,Duration of T2D (years),iGlarLixi,8% < HbA1c <= 9% (n 5 161),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,5,5,13.7 ± 7.7,Duration of T2D (years),iGlarLixi,HbA1c > 9% (n 5 69),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,5,6,12.1 ± 6.9a,Duration of T2D (years),iGlar,All completers (n 5 333),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,5,7,12.7 ± 7.1a,Duration of T2D (years),iGlar,HbA1c <= 8% (n 5 94),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,5,8,11.8 ± 6.5,Duration of T2D (years),iGlar,8% < HbA1c <= 9% (n 5 158),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,5,9,11.9 ± 7.5,Duration of T2D (years),iGlar,HbA1c >9% (n 5 81),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,6,2,31.7 ± 4.2,Screening BMI (kg/m2),iGlarLixi,All completers (n 5 327),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,6,3,31.4 ± 4.1,Screening BMI (kg/m2),iGlarLixi,HbA1c <= 8% (n 5 97),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,6,4,32.0 ± 4.3,Screening BMI (kg/m2),iGlarLixi,8% < HbA1c <= 9% (n 5 161),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,6,5,31.3 ± 4.2,Screening BMI (kg/m2),iGlarLixi,HbA1c > 9% (n 5 69),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,6,6,31.1 ± 4.2,Screening BMI (kg/m2),iGlar,All completers (n 5 333),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,6,7,31.0 ± 4.3,Screening BMI (kg/m2),iGlar,HbA1c <= 8% (n 5 94),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,6,8,31.1 ± 4.3,Screening BMI (kg/m2),iGlar,8% < HbA1c <= 9% (n 5 158),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,6,9,31.4 ± 4.2,Screening BMI (kg/m2),iGlar,HbA1c >9% (n 5 81),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,7,2,8.47 ± 0.65a,Screening HbA1c (%),iGlarLixi,All completers (n 5 327),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,7,3,7.78 ± 0.18,Screening HbA1c (%),iGlarLixi,HbA1c <= 8% (n 5 97),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,7,4,8.47 ± 0.29a,Screening HbA1c (%),iGlarLixi,8% < HbA1c <= 9% (n 5 161),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,7,5,9.45 ± 0.29,Screening HbA1c (%),iGlarLixi,HbA1c > 9% (n 5 69),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,7,6,8.52 ± 0.66a,Screening HbA1c (%),iGlar,All completers (n 5 333),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,7,7,7.77 ± 0.16,Screening HbA1c (%),iGlar,HbA1c <= 8% (n 5 94),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,7,8,8.49 ± 0.28a,Screening HbA1c (%),iGlar,8% < HbA1c <= 9% (n 5 158),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,7,9,9.46 ± 0.28a,Screening HbA1c (%),iGlar,HbA1c >9% (n 5 81),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,8,2,8.04 ± 0.67a,Baseline HbA1c (%),iGlarLixi,All completers (n 5 327),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,8,3,7.74 ± 0.58,Baseline HbA1c (%),iGlarLixi,HbA1c <= 8% (n 5 97),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,8,4,8.05 ± 0.67a,Baseline HbA1c (%),iGlarLixi,8% < HbA1c <= 9% (n 5 161),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,8,5,8.42 ± 0.60,Baseline HbA1c (%),iGlarLixi,HbA1c > 9% (n 5 69),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,8,6,8.05 ± 0.72a,Baseline HbA1c (%),iGlar,All completers (n 5 333),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,8,7,7.62 ± 0.55,Baseline HbA1c (%),iGlar,HbA1c <= 8% (n 5 94),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,8,8,8.10 ± 0.67a,Baseline HbA1c (%),iGlar,8% < HbA1c <= 9% (n 5 158),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,8,9,8.45 ± 0.75a,Baseline HbA1c (%),iGlar,HbA1c >9% (n 5 81),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,9,2,28 ± 8,Basal insulin dose at run-in (U/day),iGlarLixi,All completers (n 5 327),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,9,3,29± 8,Basal insulin dose at run-in (U/day),iGlarLixi,HbA1c <= 8% (n 5 97),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,9,4,28± 8,Basal insulin dose at run-in (U/day),iGlarLixi,8% < HbA1c <= 9% (n 5 161),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,9,5,28± 8,Basal insulin dose at run-in (U/day),iGlarLixi,HbA1c > 9% (n 5 69),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,9,6,29± 8,Basal insulin dose at run-in (U/day),iGlar,All completers (n 5 333),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,9,7,28± 8,Basal insulin dose at run-in (U/day),iGlar,HbA1c <= 8% (n 5 94),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,9,8,29± 8,Basal insulin dose at run-in (U/day),iGlar,8% < HbA1c <= 9% (n 5 158),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,9,9,30± 8,Basal insulin dose at run-in (U/day),iGlar,HbA1c >9% (n 5 81),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,10,2,35 ± 9,iGlar dose at randomization (U/day),iGlarLixi,All completers (n 5 327),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,10,3,35± 9,iGlar dose at randomization (U/day),iGlarLixi,HbA1c <= 8% (n 5 97),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,10,4,35± 10,iGlar dose at randomization (U/day),iGlarLixi,8% < HbA1c <= 9% (n 5 161),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,10,5,35 ± 9,iGlar dose at randomization (U/day),iGlarLixi,HbA1c > 9% (n 5 69),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,10,6,35± 9,iGlar dose at randomization (U/day),iGlar,All completers (n 5 333),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,10,7,34± 8,iGlar dose at randomization (U/day),iGlar,HbA1c <= 8% (n 5 94),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,10,8,36± 9,iGlar dose at randomization (U/day),iGlar,8% < HbA1c <= 9% (n 5 158),NA,NA,NA,NA,NA,NA,NA,NA,NA
29143919_1,10,9,35± 7,iGlar dose at randomization (U/day),iGlar,HbA1c >9% (n 5 81),NA,NA,NA,NA,NA,NA,NA,NA,NA
29145215_2,4,2,n = 856,NA,NA,"Individuals without diabetes, n = 3,662",NA,"baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,4,3,n = 423,NA,NA,"Individuals without diabetes, n = 3,662",NA,"baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","placebo, ",NA,NA,NA,NA,NA,NA
29145215_2,4,5,"n = 1,581",NA,NA,"Individuals without diabetes, n = 3,662",NA,"baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,4,6,n = 802,NA,NA,"Individuals without diabetes, n = 3,662",NA,"baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","placebo,",NA,NA,NA,NA,NA,NA
29145215_2,5,2,-8.2,NA,NA,"Individuals without diabetes, n = 3,662","Body weight, %","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,5,3,-2.7,NA,NA,"Individuals without diabetes, n = 3,662","Body weight, %","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","placebo, ",NA,NA,NA,NA,NA,NA
29145215_2,5,4,-5.73 (-6.47; -4.99),NA,NA,"Individuals without diabetes, n = 3,662","Body weight, %","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,5,5,-7.9,NA,NA,"Individuals without diabetes, n = 3,662","Body weight, %","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,5,6,-2.6,NA,NA,"Individuals without diabetes, n = 3,662","Body weight, %","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","placebo,",NA,NA,NA,NA,NA,NA
29145215_2,5,7,-5.20 (-5.74; -4.66),NA,NA,"Individuals without diabetes, n = 3,662","Body weight, %","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,5,8,0.26,NA,NA,"Individuals without diabetes, n = 3,662","Body weight, %",interaction p value,ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,6,2,-7.3,NA,NA,"Individuals without diabetes, n = 3,662","Body weight, kg","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,6,3,-2.4,NA,NA,"Individuals without diabetes, n = 3,662","Body weight, kg","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","placebo, ",NA,NA,NA,NA,NA,NA
29145215_2,6,4,-5.10 (-5.91; -4.29),NA,NA,"Individuals without diabetes, n = 3,662","Body weight, kg","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,6,5,-8.9,NA,NA,"Individuals without diabetes, n = 3,662","Body weight, kg","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,6,6,-3.1,NA,NA,"Individuals without diabetes, n = 3,662","Body weight, kg","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","placebo,",NA,NA,NA,NA,NA,NA
29145215_2,6,7,-5.81 (-6.40; -5.22),NA,NA,"Individuals without diabetes, n = 3,662","Body weight, kg","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,6,8,0.17,NA,NA,"Individuals without diabetes, n = 3,662","Body weight, kg",interaction p value,ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,7,2,-8.2,NA,NA,"Individuals without diabetes, n = 3,662","Waist circumference, cm","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,7,3,-3.5,NA,NA,"Individuals without diabetes, n = 3,662","Waist circumference, cm","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","placebo, ",NA,NA,NA,NA,NA,NA
29145215_2,7,4,-4.68 (-5.49; -3.87),NA,NA,"Individuals without diabetes, n = 3,662","Waist circumference, cm","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,7,5,-8.2,NA,NA,"Individuals without diabetes, n = 3,662","Waist circumference, cm","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,7,6,-4.2,NA,NA,"Individuals without diabetes, n = 3,662","Waist circumference, cm","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","placebo,",NA,NA,NA,NA,NA,NA
29145215_2,7,7,-3.90 (-4.49; -3.31),NA,NA,"Individuals without diabetes, n = 3,662","Waist circumference, cm","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,7,8,0.13,NA,NA,"Individuals without diabetes, n = 3,662","Waist circumference, cm",interaction p value,ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,8,2,-0.3,NA,NA,"Individuals without diabetes, n = 3,662","HbA1c, %","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,8,3,-0.1,NA,NA,"Individuals without diabetes, n = 3,662","HbA1c, %","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","placebo, ",NA,NA,NA,NA,NA,NA
29145215_2,8,4,-0.21 (-0.24; -0.18),NA,NA,"Individuals without diabetes, n = 3,662","HbA1c, %","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,8,5,-0.3,NA,NA,"Individuals without diabetes, n = 3,662","HbA1c, %","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,8,6,-0.1,NA,NA,"Individuals without diabetes, n = 3,662","HbA1c, %","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","placebo,",NA,NA,NA,NA,NA,NA
29145215_2,8,7,-0.24 (-0.26; -.021),NA,NA,"Individuals without diabetes, n = 3,662","HbA1c, %","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,8,8,0.17,NA,NA,"Individuals without diabetes, n = 3,662","HbA1c, %",interaction p value,ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,9,2,-0.4,NA,NA,"Individuals without diabetes, n = 3,662","FPG, mmol/l","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,9,3,0.0,NA,NA,"Individuals without diabetes, n = 3,662","FPG, mmol/l","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","placebo, ",NA,NA,NA,NA,NA,NA
29145215_2,9,4,-0.38 (-0.44; -0.32),NA,NA,"Individuals without diabetes, n = 3,662","FPG, mmol/l","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,9,5,-0.4,NA,NA,"Individuals without diabetes, n = 3,662","FPG, mmol/l","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,9,6,0.0,NA,NA,"Individuals without diabetes, n = 3,662","FPG, mmol/l","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","placebo,",NA,NA,NA,NA,NA,NA
29145215_2,9,7,-0.38 (-0.43; -0.34),NA,NA,"Individuals without diabetes, n = 3,662","FPG, mmol/l","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,9,8,0.89,NA,NA,"Individuals without diabetes, n = 3,662","FPG, mmol/l",interaction p value,ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,10,2,-3.7,NA,NA,"Individuals without diabetes, n = 3,662","SBP, mm Hg","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,10,3,-1.4,NA,NA,"Individuals without diabetes, n = 3,662","SBP, mm Hg","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","placebo, ",NA,NA,NA,NA,NA,NA
29145215_2,10,4,-2.11 (-3.36; -0.87),NA,NA,"Individuals without diabetes, n = 3,662","SBP, mm Hg","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,10,5,-4.5,NA,NA,"Individuals without diabetes, n = 3,662","SBP, mm Hg","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,10,6,-1.6,NA,NA,"Individuals without diabetes, n = 3,662","SBP, mm Hg","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","placebo,",NA,NA,NA,NA,NA,NA
29145215_2,10,7,-3.19 (-4.09; -2.28),NA,NA,"Individuals without diabetes, n = 3,662","SBP, mm Hg","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,10,8,0.17,NA,NA,"Individuals without diabetes, n = 3,662","SBP, mm Hg",interaction p value,ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,11,2,-2.5,NA,NA,"Individuals without diabetes, n = 3,662","DBP, mm Hg","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,11,3,-1.8,NA,NA,"Individuals without diabetes, n = 3,662","DBP, mm Hg","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","placebo, ",NA,NA,NA,NA,NA,NA
29145215_2,11,4,-0.75 (-1.64; 0.14),NA,NA,"Individuals without diabetes, n = 3,662","DBP, mm Hg","baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,11,5,-2.7,NA,NA,"Individuals without diabetes, n = 3,662","DBP, mm Hg","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,11,6,-1.9,NA,NA,"Individuals without diabetes, n = 3,662","DBP, mm Hg","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","placebo,",NA,NA,NA,NA,NA,NA
29145215_2,11,7,-0.95 (-1.60; -0.30),NA,NA,"Individuals without diabetes, n = 3,662","DBP, mm Hg","baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,11,8,0.73,NA,NA,"Individuals without diabetes, n = 3,662","DBP, mm Hg",interaction p value,ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,12,2,9.1,NA,NA,"Individuals without diabetes, n = 3,662",IWQOL-Lite total score (arbitrary units)#,"baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,12,3,7.1,NA,NA,"Individuals without diabetes, n = 3,662",IWQOL-Lite total score (arbitrary units)#,"baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","placebo, ",NA,NA,NA,NA,NA,NA
29145215_2,12,4,2.16 (0.65; 3.67),NA,NA,"Individuals without diabetes, n = 3,662",IWQOL-Lite total score (arbitrary units)#,"baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,12,5,11.4,NA,NA,"Individuals without diabetes, n = 3,662",IWQOL-Lite total score (arbitrary units)#,"baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,12,6,8.0,NA,NA,"Individuals without diabetes, n = 3,662",IWQOL-Lite total score (arbitrary units)#,"baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","placebo,",NA,NA,NA,NA,NA,NA
29145215_2,12,7,3.59 (2.51; 4.67),NA,NA,"Individuals without diabetes, n = 3,662",IWQOL-Lite total score (arbitrary units)#,"baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,12,8,0.13,NA,NA,"Individuals without diabetes, n = 3,662",IWQOL-Lite total score (arbitrary units)#,interaction p value,ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,13,2,10.0,NA,NA,"Individuals without diabetes, n = 3,662",IWQOL-Lite physical score (arbitrary units),"baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,13,3,7.4,NA,NA,"Individuals without diabetes, n = 3,662",IWQOL-Lite physical score (arbitrary units),"baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks","placebo, ",NA,NA,NA,NA,NA,NA
29145215_2,13,4,3.19 (1.33; 5.05),NA,NA,"Individuals without diabetes, n = 3,662",IWQOL-Lite physical score (arbitrary units),"baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,13,5,15.0,NA,NA,"Individuals without diabetes, n = 3,662",IWQOL-Lite physical score (arbitrary units),"baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","liraglutide 3.0 mg,",NA,NA,NA,NA,NA,NA
29145215_2,13,6,9.3,NA,NA,"Individuals without diabetes, n = 3,662",IWQOL-Lite physical score (arbitrary units),"baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks","placebo,",NA,NA,NA,NA,NA,NA
29145215_2,13,7,5.59 (4.26; 6.92),NA,NA,"Individuals without diabetes, n = 3,662",IWQOL-Lite physical score (arbitrary units),"baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks",ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_2,13,8,0.04,NA,NA,"Individuals without diabetes, n = 3,662",IWQOL-Lite physical score (arbitrary units),interaction p value,ETD (95% CI),NA,NA,NA,NA,NA,NA
29145215_3,4,2,n = 185,NA,NA,"Individuals with diabetes, n = 632",NA,"baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"liraglutide 3.0 mg,",NA,NA,NA,NA,NA
29145215_3,4,3,n = 88,NA,NA,"Individuals with diabetes, n = 632",NA,"baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,4,5,n = 227,NA,NA,"Individuals with diabetes, n = 632",NA,"baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,liraglutide 3.0 mg ,NA,NA,NA,NA,NA
29145215_3,4,6, n = 123,NA,NA,"Individuals with diabetes, n = 632",NA,"baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,5,2,-5.7,NA,NA,"Individuals with diabetes, n = 632","Body weight, %","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"liraglutide 3.0 mg,",NA,NA,NA,NA,NA
29145215_3,5,3,-1.8,NA,NA,"Individuals with diabetes, n = 632","Body weight, %","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,5,4,-3.95 (-5.27; -2.63),NA,NA,"Individuals with diabetes, n = 632","Body weight, %","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,5,5,-6.1,NA,NA,"Individuals with diabetes, n = 632","Body weight, %","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,liraglutide 3.0 mg ,NA,NA,NA,NA,NA
29145215_3,5,6,-2.1,NA,NA,"Individuals with diabetes, n = 632","Body weight, %","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,5,7,-4.01 (-5.15; -2.86),NA,NA,"Individuals with diabetes, n = 632","Body weight, %","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,5,8,0.95,NA,NA,"Individuals with diabetes, n = 632","Body weight, %",interaction p value,NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,6,2,-5.1,NA,NA,"Individuals with diabetes, n = 632","Body weight, kg","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"liraglutide 3.0 mg,",NA,NA,NA,NA,NA
29145215_3,6,3,-1.7,NA,NA,"Individuals with diabetes, n = 632","Body weight, kg","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,6,4,-3.43 (-4.87; -1.99),NA,NA,"Individuals with diabetes, n = 632","Body weight, kg","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,6,5,-7.1,NA,NA,"Individuals with diabetes, n = 632","Body weight, kg","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,liraglutide 3.0 mg ,NA,NA,NA,NA,NA
29145215_3,6,6,-2.5,NA,NA,"Individuals with diabetes, n = 632","Body weight, kg","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,6,7,-4.63 (-5.88; -3.38),NA,NA,"Individuals with diabetes, n = 632","Body weight, kg","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,6,8,0.22,NA,NA,"Individuals with diabetes, n = 632","Body weight, kg",interaction p value,NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,7,2,-5.4,NA,NA,"Individuals with diabetes, n = 632","Waist circumference, cm","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"liraglutide 3.0 mg,",NA,NA,NA,NA,NA
29145215_3,7,3,-2.7,NA,NA,"Individuals with diabetes, n = 632","Waist circumference, cm","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,7,4,-2.66 (-4.17; -1.16),NA,NA,"Individuals with diabetes, n = 632","Waist circumference, cm","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,7,5,-6.6,NA,NA,"Individuals with diabetes, n = 632","Waist circumference, cm","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,liraglutide 3.0 mg ,NA,NA,NA,NA,NA
29145215_3,7,6,-2.8,NA,NA,"Individuals with diabetes, n = 632","Waist circumference, cm","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,7,7,-3.54 (-4.84 ; -2.24),NA,NA,"Individuals with diabetes, n = 632","Waist circumference, cm","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,7,8,0.39,NA,NA,"Individuals with diabetes, n = 632","Waist circumference, cm",interaction p value,NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,8,2,-1.2,NA,NA,"Individuals with diabetes, n = 632","HbA1c, %","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"liraglutide 3.0 mg,",NA,NA,NA,NA,NA
29145215_3,8,3,-0.4,NA,NA,"Individuals with diabetes, n = 632","HbA1c, %","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,8,4,-0.88 (-1.10; -0.66),NA,NA,"Individuals with diabetes, n = 632","HbA1c, %","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,8,5,-1.4,NA,NA,"Individuals with diabetes, n = 632","HbA1c, %","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,liraglutide 3.0 mg ,NA,NA,NA,NA,NA
29145215_3,8,6,-0.3,NA,NA,"Individuals with diabetes, n = 632","HbA1c, %","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,8,7,-0.97 (-1.17; -0.78),NA,NA,"Individuals with diabetes, n = 632","HbA1c, %","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,8,8,0.53,NA,NA,"Individuals with diabetes, n = 632","HbA1c, %",interaction p value,NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,9,2,-1.9,NA,NA,"Individuals with diabetes, n = 632","FPG, mmol/l","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"liraglutide 3.0 mg,",NA,NA,NA,NA,NA
29145215_3,9,3,-0.1,NA,NA,"Individuals with diabetes, n = 632","FPG, mmol/l","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,9,4,-1.68 (-2.20; -1.15),NA,NA,"Individuals with diabetes, n = 632","FPG, mmol/l","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,9,5,-1.9,NA,NA,"Individuals with diabetes, n = 632","FPG, mmol/l","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,liraglutide 3.0 mg ,NA,NA,NA,NA,NA
29145215_3,9,6,0.0,NA,NA,"Individuals with diabetes, n = 632","FPG, mmol/l","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,9,7,-1.83 (-2.29; -1.37),NA,NA,"Individuals with diabetes, n = 632","FPG, mmol/l","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,9,8,0.66,NA,NA,"Individuals with diabetes, n = 632","FPG, mmol/l",interaction p value,NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,10,2,-1.9,NA,NA,"Individuals with diabetes, n = 632","SBP, mm Hg","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"liraglutide 3.0 mg,",NA,NA,NA,NA,NA
29145215_3,10,3,-0.4,NA,NA,"Individuals with diabetes, n = 632","SBP, mm Hg","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,10,4,-1.92 (-4.94; 1.09),NA,NA,"Individuals with diabetes, n = 632","SBP, mm Hg","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,10,5,-3.6,NA,NA,"Individuals with diabetes, n = 632","SBP, mm Hg","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,liraglutide 3.0 mg ,NA,NA,NA,NA,NA
29145215_3,10,6,-0.4,NA,NA,"Individuals with diabetes, n = 632","SBP, mm Hg","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,10,7,-3.11 (-5.73; -0.50),NA,NA,"Individuals with diabetes, n = 632","SBP, mm Hg","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,10,8,0.56,NA,NA,"Individuals with diabetes, n = 632","SBP, mm Hg",interaction p value,NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,11,2,-0.9,NA,NA,"Individuals with diabetes, n = 632","DBP, mm Hg","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"liraglutide 3.0 mg,",NA,NA,NA,NA,NA
29145215_3,11,3,-0.1,NA,NA,"Individuals with diabetes, n = 632","DBP, mm Hg","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,11,4,-0.49 (-2.52; 1.53),NA,NA,"Individuals with diabetes, n = 632","DBP, mm Hg","baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,11,5,-0.9,NA,NA,"Individuals with diabetes, n = 632","DBP, mm Hg","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,liraglutide 3.0 mg ,NA,NA,NA,NA,NA
29145215_3,11,6,-0.9,NA,NA,"Individuals with diabetes, n = 632","DBP, mm Hg","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,11,7,-0.25 (-2.00; 1.51),NA,NA,"Individuals with diabetes, n = 632","DBP, mm Hg","baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,11,8,0.86,NA,NA,"Individuals with diabetes, n = 632","DBP, mm Hg",interaction p value,NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,12,2,9.1,NA,NA,"Individuals with diabetes, n = 632",IWQOL-Lite total score (arbitrary units)#,"baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"liraglutide 3.0 mg,",NA,NA,NA,NA,NA
29145215_3,12,3,7.2,NA,NA,"Individuals with diabetes, n = 632",IWQOL-Lite total score (arbitrary units)#,"baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,12,4,1.34 (-1.95; 4.62),NA,NA,"Individuals with diabetes, n = 632",IWQOL-Lite total score (arbitrary units)#,"baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,12,5,14.0,NA,NA,"Individuals with diabetes, n = 632",IWQOL-Lite total score (arbitrary units)#,"baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,liraglutide 3.0 mg ,NA,NA,NA,NA,NA
29145215_3,12,6,8.0,NA,NA,"Individuals with diabetes, n = 632",IWQOL-Lite total score (arbitrary units)#,"baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,12,7,3.49 (0.62; 6.36),NA,NA,"Individuals with diabetes, n = 632",IWQOL-Lite total score (arbitrary units)#,"baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,12,8,0.33,NA,NA,"Individuals with diabetes, n = 632",IWQOL-Lite total score (arbitrary units)#,interaction p value,NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,13,2,12.1,NA,NA,"Individuals with diabetes, n = 632",IWQOL-Lite physical score (arbitrary units),"baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"liraglutide 3.0 mg,",NA,NA,NA,NA,NA
29145215_3,13,3,9.4,NA,NA,"Individuals with diabetes, n = 632",IWQOL-Lite physical score (arbitrary units),"baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,13,4,1.57 (-2.62; 5.77),NA,NA,"Individuals with diabetes, n = 632",IWQOL-Lite physical score (arbitrary units),"baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,13,5,18.0,NA,NA,"Individuals with diabetes, n = 632",IWQOL-Lite physical score (arbitrary units),"baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,liraglutide 3.0 mg ,NA,NA,NA,NA,NA
29145215_3,13,6,8.5,NA,NA,"Individuals with diabetes, n = 632",IWQOL-Lite physical score (arbitrary units),"baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,"placebo,",NA,NA,NA,NA,NA
29145215_3,13,7,7.09 (3.43; 10.74),NA,NA,"Individuals with diabetes, n = 632",IWQOL-Lite physical score (arbitrary units),"baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks",NA,ETD (95% CI),NA,NA,NA,NA,NA
29145215_3,13,8,0.05,NA,NA,"Individuals with diabetes, n = 632",IWQOL-Lite physical score (arbitrary units),interaction p value,NA,ETD (95% CI),NA,NA,NA,NA,NA
29146124_2,1,2,Primary cardiovascular endpoint,NA,Placebo,NA,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,4,2,3-83,NA,Placebo,Women,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,4,3,3-24,NA,Canakinumab,Women,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,4,4,084 (0-66-1-07),NA,Canakinumab,Women,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,5,2,4-75,NA,Placebo,Men,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,5,3,411,NA,Canakinumab,Men,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,5,4,0-86 (0-75-0-98),NA,Canakinumab,Men,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,6,2,3-38,NA,Placebo,Age <60 years,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,6,3,2-84,NA,Canakinumab,Age <60 years,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,6,4,0-83 (0-68-1-02),NA,Canakinumab,Age <60 years,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,7,2,5-43,NA,Placebo,Age >60 years,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,7,3,4-70,NA,Canakinumab,Age >60 years,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,7,4,0-86 (0-75-0-99),NA,Canakinumab,Age >60 years,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,8,2,3-88,NA,Placebo,No diabetes,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,8,3,3-21,NA,Canakinumab,No diabetes,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,8,4,0-82 (0-70-0-97),NA,Canakinumab,No diabetes,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,9,2,5-48,NA,Placebo,Diabetes,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,9,3,4-89,NA,Canakinumab,Diabetes,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,9,4,0-89 (0-75-1-05),NA,Canakinumab,Diabetes,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,10,2,4-18,NA,Placebo,Non-smoker,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,10,3,3-66,NA,Canakinumab,Non-smoker,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,10,4,0-87 (0-76-1-00),NA,Canakinumab,Non-smoker,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,11,2,5-63,NA,Placebo,Smoker,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,11,3,4-60,NA,Canakinumab,Smoker,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,11,4,0-80 (0-64-1-00),NA,Canakinumab,Smoker,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,12,2,4-72,NA,Placebo,BMI <30 kg/m2,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,12,3,4-02,NA,Canakinumab,BMI <30 kg/m2,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,12,4,0-85 (0-72-0-99),NA,Canakinumab,BMI <30 kg/m2,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,13,2,4-29,NA,Placebo,BMI >30 kg/m2,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,13,3,3-70,NA,Canakinumab,BMI >30 kg/m2,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,13,4,0-85 (0-72-1-01),NA,Canakinumab,BMI >30 kg/m2,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,14,2,3-82,NA,Placebo,LDL cholesterol <2-07 mmol/L,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,14,3,3-51,NA,Canakinumab,LDL cholesterol <2-07 mmol/L,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,14,4,0-89 (0-74-1-07),NA,Canakinumab,LDL cholesterol <2-07 mmol/L,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,15,2,5-04,NA,Placebo,LDL cholesterol >2-07 mmol/L,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,15,3,4-18,NA,Canakinumab,LDL cholesterol >2-07 mmol/L,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,15,4,0-83 (0-71-0-96),NA,Canakinumab,LDL cholesterol >2-07 mmol/L,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,16,2,3-92,NA,Placebo,hsCRP >2 to <4 mg/L,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,16,3,3-14,NA,Canakinumab,hsCRP >2 to <4 mg/L,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,16,4,0-80 (0-67-0-96),NA,Canakinumab,hsCRP >2 to <4 mg/L,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,17,2,5-07,NA,Placebo,hsCRP >4 mg/L,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,17,3,4-53,NA,Canakinumab,hsCRP >4 mg/L,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,17,4,0-88 (0-76-102),NA,Canakinumab,hsCRP >4 mg/L,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,18,2,4-42,NA,Placebo,HDL cholesterol >1-17 mmol/L,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,18,3,3-57,NA,Canakinumab,HDL cholesterol >1-17 mmol/L,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,18,4,0-80(0-68-0-95),NA,Canakinumab,HDL cholesterol >1-17 mmol/L,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,19,2,4-58,NA,Placebo,HDL cholesterol <1-17 mmol/L,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,19,3,4-15,NA,Canakinumab,HDL cholesterol <1-17 mmol/L,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,19,4,0-89 (0-76-1-04),NA,Canakinumab,HDL cholesterol <1-17 mmol/L,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,20,2,4-34,NA,Placebo,Triglycerides <1-69 mmol/L,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,20,3,3-75,NA,Canakinumab,Triglycerides <1-69 mmol/L,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,20,4,0-86 (0-74-1-01),NA,Canakinumab,Triglycerides <1-69 mmol/L,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,21,2,4-66,NA,Placebo,Triglycerides >1-69 mmol/L,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,21,3,4-05,NA,Canakinumab,Triglycerides >1-69 mmol/L,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,21,4,0-85 (0-72-1-01),NA,Canakinumab,Triglycerides >1-69 mmol/L,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29146124_2,22,2,4-50,NA,Placebo,Overall,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,22,3,3-88,NA,Canakinumab,Overall,NA,NA,NA,NA,Incidence rate per 100 person-years,NA,NA,NA,NA
29146124_2,22,4,0-85 (0-76-0-96),NA,Canakinumab,Overall,NA,NA,NA,NA,HR (95% CI),NA,NA,NA,NA
29151034_4,2,3,274 (14.6),NA,NA,NA,Permanently stopped study drug because of adverse events,NA,NA,NA,NA,Women,Placebo/Simvastatin,NA,NA
29151034_4,2,4,272 (14.3),NA,NA,NA,Permanently stopped study drug because of adverse events,NA,NA,NA,NA,Women,Ezetimibe/Simvastatin,NA,NA
29151034_4,2,5,0.85,NA,NA,NA,Permanently stopped study drug because of adverse events,NA,NA,NA,NA,Women,P Value*,NA,NA
29151034_4,2,6,0.45,NA,NA,NA,Permanently stopped study drug because of adverse events,NA,NA,NA,NA,Women,Pin/,NA,NA
29151034_4,3,3,739 (12.4),NA,NA,NA,NA,NA,NA,NA,NA,Men,Placebo/Simvastatin,NA,NA
29151034_4,3,4,778 (13.1),NA,NA,NA,NA,NA,NA,NA,NA,Men,Ezetimibe/Simvastatin,NA,NA
29151034_4,3,5,0.27,NA,NA,NA,NA,NA,NA,NA,NA,Men,P Value*,NA,NA
29151034_4,4,3,57 (2.6),NA,NA,NA,"ALT, AST, or both >3x ULN",NA,NA,NA,NA,Women,Placebo/Simvastatin,NA,NA
29151034_4,4,4,56 (2.5),NA,NA,NA,"ALT, AST, or both >3x ULN",NA,NA,NA,NA,Women,Ezetimibe/Simvastatin,NA,NA
29151034_4,4,5,0.92,NA,NA,NA,"ALT, AST, or both >3x ULN",NA,NA,NA,NA,Women,P Value*,NA,NA
29151034_4,4,6,0.50,NA,NA,NA,"ALT, AST, or both >3x ULN",NA,NA,NA,NA,Women,Pin/,NA,NA
29151034_4,5,3,151 (2.2),NA,NA,NA,NA,NA,NA,NA,NA,Men,Placebo/Simvastatin,NA,NA
29151034_4,5,4,168 (2.5),NA,NA,NA,NA,NA,NA,NA,NA,Men,Ezetimibe/Simvastatin,NA,NA
29151034_4,5,5,0.31,NA,NA,NA,NA,NA,NA,NA,NA,Men,P Value*,NA,NA
29151034_4,6,3,95 (4.3),NA,NA,NA,Gallbladder-related AEs,NA,NA,NA,NA,Women,Placebo/Simvastatin,NA,NA
29151034_4,6,4,86 (3.9),NA,NA,NA,Gallbladder-related AEs,NA,NA,NA,NA,Women,Ezetimibe/Simvastatin,NA,NA
29151034_4,6,5,0.45,NA,NA,NA,Gallbladder-related AEs,NA,NA,NA,NA,Women,P Value*,NA,NA
29151034_4,6,6,0.91,NA,NA,NA,Gallbladder-related AEs,NA,NA,NA,NA,Women,Pin/,NA,NA
29151034_4,7,3,226 (3.3),NA,NA,NA,NA,NA,NA,NA,NA,Men,Placebo/Simvastatin,NA,NA
29151034_4,7,4,196 (2.9),NA,NA,NA,NA,NA,NA,NA,NA,Men,Ezetimibe/Simvastatin,NA,NA
29151034_4,7,5,0.17,NA,NA,NA,NA,NA,NA,NA,NA,Men,P Value*,NA,NA
29151034_4,8,3,10 (0.5),NA,NA,NA,Rhabdomyolysis,NA,NA,NA,NA,Women,Placebo/Simvastatin,NA,NA
29151034_4,8,4,5 (0.2),NA,NA,NA,Rhabdomyolysis,NA,NA,NA,NA,Women,Ezetimibe/Simvastatin,NA,NA
29151034_4,8,5,0.21,NA,NA,NA,Rhabdomyolysis,NA,NA,NA,NA,Women,P Value*,NA,NA
29151034_4,8,6,0.33,NA,NA,NA,Rhabdomyolysis,NA,NA,NA,NA,Women,Pin/,NA,NA
29151034_4,9,3,8 (0.1),NA,NA,NA,NA,NA,NA,NA,NA,Men,Placebo/Simvastatin,NA,NA
29151034_4,9,4,8 (0.1),NA,NA,NA,NA,NA,NA,NA,NA,Men,Ezetimibe/Simvastatin,NA,NA
29151034_4,9,5,>0.99,NA,NA,NA,NA,NA,NA,NA,NA,Men,P Value*,NA,NA
29151034_4,10,3,15 (0.7),NA,NA,NA,Rhabdomyolysis or myopathy,NA,NA,NA,NA,Women,Placebo/Simvastatin,NA,NA
29151034_4,10,4,10 (0.4),NA,NA,NA,Rhabdomyolysis or myopathy,NA,NA,NA,NA,Women,Ezetimibe/Simvastatin,NA,NA
29151034_4,10,5,0.32,NA,NA,NA,Rhabdomyolysis or myopathy,NA,NA,NA,NA,Women,P Value*,NA,NA
29151034_4,10,6,0.21,NA,NA,NA,Rhabdomyolysis or myopathy,NA,NA,NA,NA,Women,Pin/,NA,NA
29151034_4,11,3,13 (0.2),NA,NA,NA,NA,NA,NA,NA,NA,Men,Placebo/Simvastatin,NA,NA
29151034_4,11,4,17 (0.2),NA,NA,NA,NA,NA,NA,NA,NA,Men,Ezetimibe/Simvastatin,NA,NA
29151034_4,11,5,0.47,NA,NA,NA,NA,NA,NA,NA,NA,Men,P Value*,NA,NA
29151034_4,12,3,24 (1.1),NA,NA,NA,"Rhabdomyolysis, myopathy, or myalgia with CK elevation >5x ULN",NA,NA,NA,NA,Women,Placebo/Simvastatin,NA,NA
29151034_4,12,4,13 (0.6),NA,NA,NA,"Rhabdomyolysis, myopathy, or myalgia with CK elevation >5x ULN",NA,NA,NA,NA,Women,Ezetimibe/Simvastatin,NA,NA
29151034_4,12,5,0.07,NA,NA,NA,"Rhabdomyolysis, myopathy, or myalgia with CK elevation >5x ULN",NA,NA,NA,NA,Women,P Value*,NA,NA
29151034_4,12,6,0.054,NA,NA,NA,"Rhabdomyolysis, myopathy, or myalgia with CK elevation >5x ULN",NA,NA,NA,NA,Women,Pin/,NA,NA
29151034_4,13,3,34 (0.5),NA,NA,NA,NA,NA,NA,NA,NA,Men,Placebo/Simvastatin,NA,NA
29151034_4,13,4,40 (0.6),NA,NA,NA,NA,NA,NA,NA,NA,Men,Ezetimibe/Simvastatin,NA,NA
29151034_4,13,5,0.49,NA,NA,NA,NA,NA,NA,NA,NA,Men,P Value*,NA,NA
29151034_4,14,3,145 (8.3),NA,NA,NA,Cancer,NA,NA,NA,NA,Women,Placebo/Simvastatin,NA,NA
29151034_4,14,4,144 (8.2),NA,NA,NA,Cancer,NA,NA,NA,NA,Women,Ezetimibe/Simvastatin,NA,NA
29151034_4,14,5,0.97,NA,NA,NA,Cancer,NA,NA,NA,NA,Women,P Value*,NA,NA
29151034_4,14,6,0.83,NA,NA,NA,Cancer,NA,NA,NA,NA,Women,Pin/,NA,NA
29151034_4,15,3,587 (10.8),NA,NA,NA,NA,NA,NA,NA,NA,Men,Placebo/Simvastatin,NA,NA
29151034_4,15,4,604 (10.8),NA,NA,NA,NA,NA,NA,NA,NA,Men,Ezetimibe/Simvastatin,NA,NA
29151034_4,15,5,0.53,NA,NA,NA,NA,NA,NA,NA,NA,Men,P Value*,NA,NA
29151034_5,2,3,50 (2.3),NA,NA,NA,"ALT, AST, or both >3x ULN",NA,NA,NA,NA,Women,NA,Placebo/Simvastatin,NA
29151034_5,2,4,52 (2.4),NA,NA,NA,"ALT, AST, or both >3x ULN",NA,NA,NA,NA,Women,NA,Ezetimibe/Simvastatin,NA
29151034_5,2,5,0.92,NA,NA,NA,"ALT, AST, or both >3x ULN",NA,NA,NA,NA,Women,NA,P Value*,NA
29151034_5,2,6,0.82,NA,NA,NA,"ALT, AST, or both >3x ULN",NA,NA,NA,NA,Women,NA,Pin/,NA
29151034_5,3,3,143 (2.1),NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,Placebo/Simvastatin,NA
29151034_5,3,4,153 (2.3),NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,Ezetimibe/Simvastatin,NA
29151034_5,3,5,0.56,NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,P Value*,NA
29151034_5,4,3,72 (3.4),NA,NA,NA,Gallbladder-related AEs,NA,NA,NA,NA,Women,NA,Placebo/Simvastatin,NA
29151034_5,4,4,63 (2.9),NA,NA,NA,Gallbladder-related AEs,NA,NA,NA,NA,Women,NA,Ezetimibe/Simvastatin,NA
29151034_5,4,5,0.38,NA,NA,NA,Gallbladder-related AEs,NA,NA,NA,NA,Women,NA,P Value*,NA
29151034_5,4,6,0.93,NA,NA,NA,Gallbladder-related AEs,NA,NA,NA,NA,Women,NA,Pin/,NA
29151034_5,5,3,180 (2.7),NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,Placebo/Simvastatin,NA
29151034_5,5,4,151 (2.3),NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,Ezetimibe/Simvastatin,NA
29151034_5,5,5,0.13,NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,P Value*,NA
29151034_5,6,3,10 (0.5),NA,NA,NA,Rhabdomyolysis,NA,NA,NA,NA,Women,NA,Placebo/Simvastatin,NA
29151034_5,6,4,4 (0.2),NA,NA,NA,Rhabdomyolysis,NA,NA,NA,NA,Women,NA,Ezetimibe/Simvastatin,NA
29151034_5,6,5,0.12,NA,NA,NA,Rhabdomyolysis,NA,NA,NA,NA,Women,NA,P Value*,NA
29151034_5,6,6,0.22,NA,NA,NA,Rhabdomyolysis,NA,NA,NA,NA,Women,NA,Pin/,NA
29151034_5,7,3,8 (0.1),NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,Placebo/Simvastatin,NA
29151034_5,7,4,8 (0.1),NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,Ezetimibe/Simvastatin,NA
29151034_5,7,5,>0.99,NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,P Value*,NA
29151034_5,8,3,4 (0.2),NA,NA,NA,Myopathy,NA,NA,NA,NA,Women,NA,Placebo/Simvastatin,NA
29151034_5,8,4,5 (0.2),NA,NA,NA,Myopathy,NA,NA,NA,NA,Women,NA,Ezetimibe/Simvastatin,NA
29151034_5,8,5,"NA",NA,NA,NA,Myopathy,NA,NA,NA,NA,Women,NA,P Value*,NA
29151034_5,8,6,0.76,NA,NA,NA,Myopathy,NA,NA,NA,NA,Women,NA,Pin/,NA
29151034_5,9,3,5 (0.1),NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,Placebo/Simvastatin,NA
29151034_5,9,4,8 (0.1),NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,Ezetimibe/Simvastatin,NA
29151034_5,9,5,0.42,NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,P Value*,NA
29151034_5,10,3,21 (1.0),NA,NA,NA,"Rhabdomyolysis, myopathy, or myalgia with CK elevation >5x ULN",NA,NA,NA,NA,Women,NA,Placebo/Simvastatin,NA
29151034_5,10,4,12 (0.6),NA,NA,NA,"Rhabdomyolysis, myopathy, or myalgia with CK elevation >5x ULN",NA,NA,NA,NA,Women,NA,Ezetimibe/Simvastatin,NA
29151034_5,10,5,0.12,NA,NA,NA,"Rhabdomyolysis, myopathy, or myalgia with CK elevation >5x ULN",NA,NA,NA,NA,Women,NA,P Value*,NA
29151034_5,10,6,0.16,NA,NA,NA,"Rhabdomyolysis, myopathy, or myalgia with CK elevation >5x ULN",NA,NA,NA,NA,Women,NA,Pin/,NA
29151034_5,11,3,34 (0.5),NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,Placebo/Simvastatin,NA
29151034_5,11,4,35 (0.5),NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,Ezetimibe/Simvastatin,NA
29151034_5,11,5,0.90,NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,P Value*,NA
29151034_5,12,3,102 (4.8),NA,NA,NA,Cancer,NA,NA,NA,NA,Women,NA,Placebo/Simvastatin,NA
29151034_5,12,4,111 (5.1),NA,NA,NA,Cancer,NA,NA,NA,NA,Women,NA,Ezetimibe/Simvastatin,NA
29151034_5,12,5,0.62,NA,NA,NA,Cancer,NA,NA,NA,NA,Women,NA,P Value*,NA
29151034_5,12,6,0.41,NA,NA,NA,Cancer,NA,NA,NA,NA,Women,NA,Pin/,NA
29151034_5,13,3,453 (6.7),NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,Placebo/Simvastatin,NA
29151034_5,13,4,454 (6.8),NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,Ezetimibe/Simvastatin,NA
29151034_5,13,5,0.92,NA,NA,NA,NA,NA,NA,NA,NA,Men,NA,P Value*,NA
29299340_1,3,2,51.0 (12.5),"Age (years), mean (SD)","PBO, n=69",cDMARD,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,3,3,49.1 (10.0),"Age (years), mean (SD)","IXEQ4W, n=68",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,3,4,49.3 (12.8),"Age (years), mean (SD)","IXEQ2W, n=63",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,3,5,51.3 (12.8),"Age (years), mean (SD)","PBO, n=59",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,3,6,49.9 (10.3),"Age (years), mean (SD)","IXEQ4W, n=57",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,3,7,50.1 (12.7),"Age (years), mean (SD)","IXEQ2W, n=53",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,3,8,49.9 (12.1),"Age (years), mean (SD)","PBO, n=37",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,3,9,49.1 (10.4),"Age (years), mean (SD)","IXEQ4W, n=39",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,3,10,50.5 (12.4),"Age (years), mean (SD)","IXEQ2W, n=40",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,4,2,32 (46.4),"Male, n (%)","PBO, n=69",cDMARD,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,4,3,29 (42.6),"Male, n (%)","IXEQ4W, n=68",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,4,4,27 (42.9),"Male, n (%)","IXEQ2W, n=63",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,4,5,25 (42.4),"Male, n (%)","PBO, n=59",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,4,6,24 (42.1),"Male, n (%)","IXEQ4W, n=57",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,4,7,23 (43.4),"Male, n (%)","IXEQ2W, n=53",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,4,8,16 (43.2),"Male, n (%)","PBO, n=37",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,4,9,16 (41.0),"Male, n (%)","IXEQ4W, n=39",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,4,10,21 (52.5),"Male, n (%)","IXEQ2W, n=40",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,5,2,84.8 (19.7),"Weight (kg), mean (SD)","PBO, n=69",cDMARD,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,5,3,83.5 (19.5),"Weight (kg), mean (SD)","IXEQ4W, n=68",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,5,4,81.0 (16.7),"Weight (kg), mean (SD)","IXEQ2W, n=63",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,5,5,84.87 (20.1),"Weight (kg), mean (SD)","PBO, n=59",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,5,6,84.58 (20.0),"Weight (kg), mean (SD)","IXEQ4W, n=57",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,5,7,81.88 (15.8),"Weight (kg), mean (SD)","IXEQ2W, n=53",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,5,8,81.8 (19.6),"Weight (kg), mean (SD)","PBO, n=37",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,5,9,88.9 (28.0),"Weight (kg), mean (SD)","IXEQ4W, n=39",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,5,10,82.6 (18.8),"Weight (kg), mean (SD)","IXEQ2W, n=40",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,6,2,6.1 (7.4),"Time since PsA diagnosis (years), mean (SD)","PBO, n=69",cDMARD,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,6,3,5.6 (5.8),"Time since PsA diagnosis (years), mean (SD)","IXEQ4W, n=68",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,6,4,7.4 (7.4),"Time since PsA diagnosis (years), mean (SD)","IXEQ2W, n=63",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,6,5,6.1 (7.6),"Time since PsA diagnosis (years), mean (SD)","PBO, n=59",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,6,6,5.1 (5.3),"Time since PsA diagnosis (years), mean (SD)","IXEQ4W, n=57",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,6,7,7.8 (7.8),"Time since PsA diagnosis (years), mean (SD)","IXEQ2W, n=53",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,6,8,6.8 (5.8),"Time since PsA diagnosis (years), mean (SD)","PBO, n=37",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,6,9,7.3 (7.3),"Time since PsA diagnosis (years), mean (SD)","IXEQ4W, n=39",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,6,10,7.0 (9.1),"Time since PsA diagnosis (years), mean (SD)","IXEQ2W, n=40",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,7,2,19.5 (12.8),"Tender joint count (68 joints), mean (SD)","PBO, n=69",cDMARD,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,7,3,20.6 (13.3),"Tender joint count (68 joints), mean (SD)","IXEQ4W, n=68",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,7,4,21.4 (15.1),"Tender joint count (68 joints), mean (SD)","IXEQ2W, n=63",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,7,5,20.6 (13.4),"Tender joint count (68 joints), mean (SD)","PBO, n=59",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,7,6,20.5 (13.8),"Tender joint count (68 joints), mean (SD)","IXEQ4W, n=57",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,7,7,21.1 (15.6),"Tender joint count (68 joints), mean (SD)","IXEQ2W, n=53",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,7,8,18.6 (13.4),"Tender joint count (68 joints), mean (SD)","PBO, n=37",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,7,9,20.3 (14.4),"Tender joint count (68 joints), mean (SD)","IXEQ4W, n=39",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,7,10,21.8 (12.4),"Tender joint count (68 joints), mean (SD)","IXEQ2W, n=40",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,8,2,10.9 (7.7),"Swollen joint count (66 joints), mean (SD)","PBO, n=69",cDMARD,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,8,3,10.8 (7.4),"Swollen joint count (66 joints), mean (SD)","IXEQ4W, n=68",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,8,4,11.8 (7.6),"Swollen joint count (66 joints), mean (SD)","IXEQ2W, n=63",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,8,5,11.3 (8.1),"Swollen joint count (66 joints), mean (SD)","PBO, n=59",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,8,6,10.8 (7.9),"Swollen joint count (66 joints), mean (SD)","IXEQ4W, n=57",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,8,7,11.4 (6.0),"Swollen joint count (66 joints), mean (SD)","IXEQ2W, n=53",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,8,8,10.1 (6.4),"Swollen joint count (66 joints), mean (SD)","PBO, n=37",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,8,9,12.6 (9.4),"Swollen joint count (66 joints), mean (SD)","IXEQ4W, n=39",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,8,10,12.5 (6.7),"Swollen joint count (66 joints), mean (SD)","IXEQ2W, n=40",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,9,2,1.19 (0.60),"HAQ-DI total score, mean (SD)","PBO, n=69",cDMARD,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,9,3,1.25 (0.54),"HAQ-DI total score, mean (SD)","IXEQ4W, n=68",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,9,4,1.23 (0.55),"HAQ-DI total score, mean (SD)","IXEQ2W, n=63",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,9,5,1.21 (0.60),"HAQ-DI total score, mean (SD)","PBO, n=59",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,9,6,1.21 (0.53),"HAQ-DI total score, mean (SD)","IXEQ4W, n=57",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,9,7,1.25 (0.57),"HAQ-DI total score, mean (SD)","IXEQ2W, n=53",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,9,8,1.09 (0.62),"HAQ-DI total score, mean (SD)","PBO, n=37",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,9,9,1.22 (0.56),"HAQ-DI total score, mean (SD)","IXEQ4W, n=39",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,9,10,1.09 (0.59),"HAQ-DI total score, mean (SD)","IXEQ2W, n=40",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,10,2,18.9 (32.2),"van der Heijde mTSS, mean (SD)","PBO, n=69",cDMARD,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,10,3,21.2 (36.9),"van der Heijde mTSS, mean (SD)","IXEQ4W, n=68",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,10,4,17.3 (32.7),"van der Heijde mTSS, mean (SD)","IXEQ2W, n=63",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,10,5,17 (28.6),"van der Heijde mTSS, mean (SD)","PBO, n=59",MTX,NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,10,6,21 (38.4),"van der Heijde mTSS, mean (SD)","IXEQ4W, n=57",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,10,7,19.2 (35.2),"van der Heijde mTSS, mean (SD)","IXEQ2W, n=53",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,10,8,15.3 (21.6),"van der Heijde mTSS, mean (SD)","PBO, n=37",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,10,9,15.7 (23.9),"van der Heijde mTSS, mean (SD)","IXEQ4W, n=39",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29299340_1,10,10,11.9 (21.4),"van der Heijde mTSS, mean (SD)","IXEQ2W, n=40",None (cDMARD-naive or past use at baseline),NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,1,2,Open-label population,NA,ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,1,3,Randomize,NA,ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,1,4,d population,NA,ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,3,2,48.4 (11.9),"Age, years",ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,3,3,48.1 (12.0),"Age, years",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,3,5,46.4 (12.2),"Age, years",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,3,7,48.3 (12.2),"Age, years",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,4,2,694 (83.2),"Female, n (%)",ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,4,3,164 (81.2),"Female, n (%)",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,4,5,157 (77.7),"Female, n (%)",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,4,7,167 (83.5),"Female, n (%)",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,5,2,158 (18.9),"Prior tobacco use, n (%)",ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,5,3,42 (20.8),"Prior tobacco use, n (%)",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,5,5,31 (15.4),"Prior tobacco use, n (%)",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,5,7,39 (19.5),"Prior tobacco use, n (%)",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,6,2,6.9 (7.0),"Disease duration, years",ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,6,3,6.8 (7.2),"Disease duration, years",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,6,5,6.4 (7.1),"Disease duration, years",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,6,7,7.3 (6.7),"Disease duration, years",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,7,2,642 (77.6),"ACPA positive, n (%)",ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,7,3,161 (80.1),"ACPA positive, n (%)",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,7,5,156 (77.6),"ACPA positive, n (%)",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,7,7,156 (78.8),"ACPA positive, n (%)",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,8,2,603 (72.7),"RF positive, n (%)",ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,8,3,147 (73.1),"RF positive, n (%)",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,8,5,142 (70.7),"RF positive, n (%)",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,8,7,147 (74.2),"RF positive, n (%)",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,9,2,ETN 50 mg + MTX N = 834,Clinical and patient-reported characteristics at baseline and randomization,ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,9,3,ETN 50 mg + MTX n = 201,Clinical and patient-reported characteristics at baseline and randomization,ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,9,5,ETN 25 mg + MTX n = 201,Clinical and patient-reported characteristics at baseline and randomization,ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,9,7,MTX n = 197,Clinical and patient-reported characteristics at baseline and randomization,MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,10,2,Week 0,NA,ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,10,3,Week 0,NA,ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,10,4,Week 36,NA,ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,10,5,Week 0,NA,ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,10,6,Week 36,NA,ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,10,7,Week 0,NA,MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,10,8,Week 36,NA,MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,11,2,4.4 (0.4),DAS28,ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,11,3,4.3 (0.5),DAS28,ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,11,4,2.0 (0.6),DAS28,ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,11,5,4.4 (0.4),DAS28,ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,11,6,2.1 (0.6),DAS28,ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,11,7,4.3 (0.4),DAS28,MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,11,8,2.1 (0.6),DAS28,MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,12,2,19.1 (5.1),SDAI,ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,12,3,18.7 (4.8),SDAI,ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,12,4,4.7 (3.6),SDAI,ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,12,5,19.2 (5.1),SDAI,ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,12,6,4.8 (3.2),SDAI,ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,12,7,18.8 (5.4),SDAI,MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,12,8,4.8 (3.2),SDAI,MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,13,2,17.8 (5.0),CDAI,ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,13,3,17.5 (4.6),CDAI,ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,13,4,4.1 (3.5),CDAI,ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,13,5,17.9 (5.0),CDAI,ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,13,6,4.2 (3.2),CDAI,ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,13,7,17.8 (5.3),CDAI,MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,13,8,4.3 (3.2),CDAI,MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,14,2,5.1 (2.9),"TJC, 0-28",ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,14,3,4.7 (2.7),"TJC, 0-28",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,14,4,0.6 (1.2),"TJC, 0-28",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,14,5,5.2 (2.9),"TJC, 0-28",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,14,6,0.7 (1.3),"TJC, 0-28",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,14,7,5.1 (2.9),"TJC, 0-28",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,14,8,0.7 (1.2),"TJC, 0-28",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,15,2,3.8 (2.6),"SJC, 0-28",ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,15,3,3.9 (2.7),"SJC, 0-28",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,15,4,0.6 (1.5),"SJC, 0-28",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,15,5,3.8 (2.6),"SJC, 0-28",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,15,6,0.6 (1.2),"SJC, 0-28",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,15,7,4.0 (2.7),"SJC, 0-28",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,15,8,0.6 (1.1),"SJC, 0-28",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,16,2,12.3 (16.4),"CRP, mg/L",ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,16,3,11.9 (13.9),"CRP, mg/L",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,16,4,5.9 (5.9),"CRP, mg/L",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,16,5,12.8 (18.0),"CRP, mg/L",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,16,6,6.0 (6.5),"CRP, mg/L",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,16,7,10.4 (13.1),"CRP, mg/L",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,16,8,5.2 (3.3),"CRP, mg/L",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,17,2,22.2 (13.1),"ESR, 0-100 mm/hour",ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,17,3,22.2 (12.9),"ESR, 0-100 mm/hour",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,17,4,9.9 (7.2),"ESR, 0-100 mm/hour",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,17,5,21.7 (13.4),"ESR, 0-100 mm/hour",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,17,6,10.7 (8.6),"ESR, 0-100 mm/hour",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,17,7,20.4 (12.1),"ESR, 0-100 mm/hour",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,17,8,9.6 (6.0),"ESR, 0-100 mm/hour",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,18,2,4.1 (1.3),"PGA, 0-10",ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,18,3,4.0 (1.3),"PGA, 0-10",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,18,4,1.1 (0.9),"PGA, 0-10",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,18,5,4.0 (1.3),"PGA, 0-10",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,18,6,1.2 (1.1),"PGA, 0-10",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,18,7,4.2 (1.3),"PGA, 0-10",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,18,8,1.1 (0.8),"PGA, 0-10",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,19,2,4.9 (1.7),"PtGA, 0-10",ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,19,3,4.9 (1.8),"PtGA, 0-10",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,19,4,1.8 (1.7),"PtGA, 0-10",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,19,5,4.8 (1.7),"PtGA, 0-10",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,19,6,1.8 (1.5),"PtGA, 0-10",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,19,7,4.6 (1.7),"PtGA, 0-10",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,19,8,1.9 (1.6),"PtGA, 0-10",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,20,2,43.4 (17.0),"General health VAS, 0-100 mm",ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,20,3,43.2 (17.3),"General health VAS, 0-100 mm",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,20,4,14.1 (15.8),"General health VAS, 0-100 mm",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,20,5,41.5 (15.5),"General health VAS, 0-100 mm",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,20,6,14.8 (15.0),"General health VAS, 0-100 mm",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,20,7,40.9 (15.6),"General health VAS, 0-100 mm",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,20,8,15.1 (15.5),"General health VAS, 0-100 mm",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,21,2,45.5 (17.4),"Pain VAS, 0-100 mm",ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,21,3,46.1 (17.8),"Pain VAS, 0-100 mm",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,21,4,12.8 (15.5),"Pain VAS, 0-100 mm",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,21,5,43.1 (16.1),"Pain VAS, 0-100 mm",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,21,6,13.8 (14.8),"Pain VAS, 0-100 mm",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,21,7,44.1 (16.3),"Pain VAS, 0-100 mm",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,21,8,14.2 (15.6),"Pain VAS, 0-100 mm",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,22,2,1.1 (0.6),"Total HAQ, 0-3",ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,22,3,1.1 (0.6),"Total HAQ, 0-3",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,22,4,0.5 (0.5),"Total HAQ, 0-3",ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,22,5,1.1 (0.6),"Total HAQ, 0-3",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,22,6,0.5 (0.5),"Total HAQ, 0-3",ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,22,7,1.1 (0.6),"Total HAQ, 0-3",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,22,8,0.5 (0.4),"Total HAQ, 0-3",MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,23,2,ETN 50 mg + MTX N = 709,Radiographic characteristics at baseline and randomization,ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,23,3,ETN 50 mg + MTX n = 184,Radiographic characteristics at baseline and randomization,ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,23,5,ETN 25 mg + MTX n = 184,Radiographic characteristics at baseline and randomization,ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,23,7,MTX n = 167,Radiographic characteristics at baseline and randomization,MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,24,2,Week 0,NA,ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,24,3,Week 0,NA,ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,24,4,Week 36,NA,ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,24,5,Week 0,NA,ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,24,6,Week 36,NA,ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,24,7,Week 0,NA,MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,24,8,Week 36,NA,MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,25,2,39.3 (55.3),mTSS (0-448),ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,25,3,42.6 (58.8),mTSS (0-448),ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,25,4,42.7 (58.8),mTSS (0-448),ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,25,5,39.1 (60.3),mTSS (0-448),ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,25,6,38.9 (59.8),mTSS (0-448),ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,25,7,42.3 (47.5),mTSS (0-448),MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,25,8,42.4 (47.6),mTSS (0-448),MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,26,2,24.8 (33.2),Erosion score (0-280),ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,26,3,25.8 (34.6),Erosion score (0-280),ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,26,4,25.8 (34.6),Erosion score (0-280),ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,26,5,24.7 (36.8),Erosion score (0-280),ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,26,6,24.7 (36.5),Erosion score (0-280),ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,26,7,26.2 (28.1),Erosion score (0-280),MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,26,8,26.1 (28.1),Erosion score (0-280),MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,27,2,14.5 (23.6),JSN score (0-168),ETN 50 mg + MTX N = 834,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,27,3,16.8 (25.3),JSN score (0-168),ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,27,4,16.9 (25.4),JSN score (0-168),ETN 50 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,27,5,14.4 (24.8),JSN score (0-168),ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,27,6,14.2 (24.6),JSN score (0-168),ETN 25 mg + MTX n = 202,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,27,7,16.1 (21.1),JSN score (0-168),MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29338762_1,27,8,16.1 (21.2),JSN score (0-168),MTX n = 200,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
29406853_1,2,2,63 (57-70),"Age, yrs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"MVD (n - 12,558)"
29406853_1,2,3,68 (62-73),"Age, yrs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No MVD (n - 8,600)"
29406853_1,2,4,<0.0001,"Age, yrs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,p Value
29406853_1,3,2,"10,149 (81.0)",Male,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"MVD (n - 12,558)"
29406853_1,3,3,"5,951 (69.2)",Male,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No MVD (n - 8,600)"
29406853_1,3,4,<0.0001,Male,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,p Value
29406853_1,4,2,"10,746 (85.6)",Caucasian,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"MVD (n - 12,558)"
29406853_1,4,3,"7,579 (88.1)",Caucasian,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No MVD (n - 8,600)"
29406853_1,4,4,<0.0001,Caucasian,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,p Value
29406853_1,5,2,"3,480 (27.7)",Diabetes mellitus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"MVD (n - 12,558)"
29406853_1,5,3,"3,324 (38.7)",Diabetes mellitus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No MVD (n - 8,600)"
29406853_1,5,4,<0.0001,Diabetes mellitus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,p Value
29406853_1,6,2,"9,603 (76.5)",Hypertension,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"MVD (n - 12,558)"
29406853_1,6,3,"6,800 (79.1)",Hypertension,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No MVD (n - 8,600)"
29406853_1,6,4,<0.0001,Hypertension,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,p Value
29406853_1,7,2,"9,881 (78.7)",Hyperlipidemia,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"MVD (n - 12,558)"
29406853_1,7,3,"6,359 (74.0)",Hyperlipidemia,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No MVD (n - 8,600)"
29406853_1,7,4,<0.0001,Hyperlipidemia,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,p Value
29406853_1,8,2,"2,322 (18.5)",Smoking,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"MVD (n - 12,558)"
29406853_1,8,3,"1,212 (14.1)",Smoking,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No MVD (n - 8,600)"
29406853_1,8,4,<0.0001,Smoking,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,p Value
29406853_1,9,2,"2,630 (21.2)",eGFR <60 ml/min/1.73 m2*,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"MVD (n - 12,558)"
29406853_1,9,3,"2,218 (26.1)",eGFR <60 ml/min/1.73 m2*,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No MVD (n - 8,600)"
29406853_1,9,4,<0.0001,eGFR <60 ml/min/1.73 m2*,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,p Value
29406853_1,10,2,"2,199 (17.5)",CHF,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"MVD (n - 12,558)"
29406853_1,10,3,"2,025 (23.5)",CHF,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No MVD (n - 8,600)"
29406853_1,10,4,<0.0001,CHF,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,p Value
29406853_1,11,2,736 (5.9),PAD,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"MVD (n - 12,558)"
29406853_1,11,3,407 (4.7),PAD,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No MVD (n - 8,600)"
29406853_1,11,4,<0.0001,PAD,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,p Value
29406853_1,12,2,"6,897 (55.0)",Qualifying MI: STEMI,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"MVD (n - 12,558)"
29406853_1,12,3,"4,432 (51.6)",Qualifying MI: STEMI,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No MVD (n - 8,600)"
29406853_1,12,4,<0.0001,Qualifying MI: STEMI,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,p Value
29406853_1,13,2,858 (6.8),Prior CABG,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"MVD (n - 12,558)"
29406853_1,13,3,117 (1.4),Prior CABG,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No MVD (n - 8,600)"
29406853_1,13,4,<0.0001,Prior CABG,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,p Value
29406853_1,14,2,"11,679 (93.0)",Prior PCI,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"MVD (n - 12,558)"
29406853_1,14,3,"5,888 (68.5)",Prior PCI,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"No MVD (n - 8,600)"
29406853_1,14,4,<0.0001,Prior PCI,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,p Value
